The activity of CEM-101, a fluoroketolide, was compared to those of 11 other antimicrobial agents using the reference broth microdilution method tested against 103 Neisseria meningitidis strains, including ciprofloxacinnonsusceptible isolates with confirmed gyrA (T91I) mutations. Among the tested isolates, 79.6% were serogroup B or C and all isolates were susceptible to ceftriaxone, azithromycin, minocycline, and rifampin. However, penicillin-nonsusceptible strains were observed (15.5%) and susceptibility to trimethoprim-sulfamethoxazole was only 50.5%. CEM-101 was the most active macrolide-like compound (MIC 90 , <0.015 g/ml) compared with MIC 90 s of telithromycin (MIC 90 , 0.03 g/ml), azithromycin and clarithromycin (MIC 90 , 0.12 g/ml), and erythromycin (MIC 90 , 0.25 g/ml). CEM-101 could provide a potent alternative for the prophylaxis of meningococcal disease.
Currently, chemoprophylaxis is recommended for preventing the spread of bacterial meningitis caused by Neisseria meningitidis among nonimmune persons having contact with patients with active disease. In order to be an effective prophylactic agent, an appropriate antimicrobial agent must achieve concentrations in nasal secretions. Several antimicrobial classes have been traditionally recommended and utilized for nasopharyngeal decolonization (3), including ␤-lactams, ansamycins (rifampin), fluoroquinolones, sulfonamides (also trimethoprim-sulfamethoxazole [TMP-SMX]), and macrolides. Unfortunately, resistance or reduced susceptibility has been documented among N. meningitidis isolates for all of these antimicrobial classes (9, 11, 13, (16) (17) (18) 20) . A recent report documented the emergence of fluoroquinolone-resistant N. meningitidis in the United States, and the high rates of resistance to TMP-SMX in this species observed in some studies raise serious concern about the continued use of these agents either for decolonization or as prophylactic agents (4, 22) . Among macrolide agents, only azithromycin has been included in the Clinical and Laboratory Standards Institute (CLSI) guidelines for providing susceptibility breakpoint criteria for prophylaxis of meningococcal case contacts and these criteria are not to be utilized for therapy of patients with invasive meningococcal disease (7) . Azithromycin was shown to have an eradication rate (ER) comparable to that of rifampin, with posttreatment ER at Ͼ91% for both drugs (12) . The serious nature of disease caused by N. meningitidis and the evolution of resistance to currently used therapies for invasive infections and colonization suggest that the use of newer agents within other classes should be considered.
The ketolides are structurally similar to the macrolides among the macrolide-lincosamide-streptogramin (MLS B ) group. CEM-101 is a novel fluoroketolide agent being developed for parenteral and oral therapy targeted to treat moderate-to-severe community-acquired bacterial pneumonia and other indications. This antimicrobial agent has significant potency and activity against several bacterial species, including macrolide-resistant organisms (14) . This study was initiated to provide comprehensive data on the activity of CEM-101, to facilitate development as a potential alternative chemoprophylaxis agent in the eradication of nasopharyngeal colonization of N. meningitidis, and to prevent transmission to nonimmune contacts. CEM-101 and comparison agents were tested against a global collection of N. meningitidis isolates, including those with reduced susceptibility to fluoroquinolones (22) .
A total of 100 bacteremic N. meningitidis isolates from the SENTRY Antimicrobial Surveillance Program were collected from participating medical centers located in North America (58 isolates), Latin America (13 from three countries), Europe (31 from eight countries), and the Asia-Pacific region (1 isolate). Isolates were collected from patient bloodstream infections during 1997 to 2009 and were identified by at least three laboratories, including two reference laboratories (JMI Laboratories, North Liberty, IA, and the University of Iowa Hygienic Laboratory, Coralville, IA).
Four isolates from the SENTRY Program had elevated nalidixic acid MIC values of Ն8 g/ml (data not shown), which can correlate with diminished susceptibility to fluoroquinolones according to the CLSI. These isolates were all recovered from European patients in Poland (one isolate), Switzerland (one isolate), and Sweden (two isolates, temporally related). However, all nalidixic acid-nonsusceptible strains had susceptible-level fluoroquinolone MIC results. Three additional isolates of ciprofloxacin-nonsusceptible meningococci from the United States (22) were provided by the Active Bacterial Core Surveillance (ABCs), a collaboration between the Centers for Disease Control and Prevention (Atlanta, GA) and several state health departments and universities participating in the Emerging Infections Program Network.
Antimicrobial agents tested included CEM-101, telithromycin, azithromycin, clarithromycin, erythromycin, penicillin, ceftriaxone, ciprofloxacin, levofloxacin, minocycline, rifampin, and TMP-SMX. CLSI reference broth microdilution (6) methodology was performed using cation-adjusted Mueller-Hinton broth panels supplemented with 2.5 to 5% lysed horse blood as well as recommended safety precautions described by the CLSI (7). Direct colony suspensions from a 20-to 24-h growth from a chocolate agar plate were used to obtain a 0.5 McFarland standard inoculum. Panels were incubated at 35°C in 5% CO 2 for 20 to 24 h. Quality control (QC) was performed during each testing event using Streptococcus pneumoniae ATCC 49619 (7) . QC strains Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213 were used to control MIC ranges for ciprofloxacin and minocycline. All MIC values were within specified QC ranges (7).
Isolates were tested for serogroup identification by the University of Iowa Hygienic Laboratory using four antisera which were supplied by Remel Europe Ltd. (Crossways, United Kingdom) (groups B and W135) and Becton Dickinson (Franklin Lakes, NJ) (groups C and Y).
Three strains with elevated fluoroquinolone MIC values (MIC at Ն0.06 g/ml) were evaluated for the presence of mutations in quinolone resistance-determining regions (QRDR) of gyrA, gyrB, parC, and parE and for alterations in the efflux pump regulator gene mtrR. The primers sets used were as follows: parC-F, GCT CGG CCG ATA CGC CGA ACG 3Ј; parC-R, 5ЈCAA TCG CCG CCT GCG TGA CTT C 3Ј; parE-F, 5ЈGAC AAR CTG ACC AAC CGC GAC 3Ј; parE-R, 5ЈCGT AGA TGT GTC CGT CGG CRA C 3Ј; gyrA-F, 5ЈATG ACC GAC GCA ACC ATC CGC 3Ј; gyrA-R, 5ЈGAC GAG CCG TTG ACG AGC AGT G 3Ј; gyrB-F, 5ЈGCG ATT CTG CAG GCG GTT CC 3Ј; and gyrB-R, 5ЈTAT AGA TGT AGC CGC GCT CG 3Ј. The mtrR gene was amplified using oligonucleotides mtrR-F1 (5ЈACC TGA TGC TTG CCG CCT TG 3Ј) and mtrR-R1 (5ЈTTC GCA GGA AGA GAA CCA CC 3Ј) and sequenced using these two and one additional primer, mtrR-R2 (5ЈCCA GAT TGC CTG ATG CTT GC 3Ј). Amplicons were sequenced on both strands, and sequences obtained were analyzed using Lasergene (DNA Star, Madison, WI) software and compared to sequences available on the internet.
All but five isolates were typeable using the four antisera available. The vast majority (79.6%) of isolates were either serogroup B (41.7%) or serogroup C (37.9%), with smaller numbers of serogoups Y (12.6%) and W-135 (2.9%). In this international surveillance collection of isolates, penicillin-resistant (MIC, Ͼ0.25 g/ml) isolates were not detected (Table  1) . However, 16 isolates were nonsusceptible to penicillin, with a susceptibility rate of only 84.5%. Penicillin-nonsusceptible isolates were observed among the three most common serogroups, including B (9 strains), C (3 strains), and Y (2 strains), as well as two strains that were not typeable. All isolates were susceptible to ceftriaxone, azithromycin, minocycline, and rifampin using currently recommended susceptibility breakpoints for these agents. Susceptibility to TMP-SMX was only 50.5%, and resistance to this agent was observed among all four serogroups. All but three isolates were very susceptible (MICs, Յ0.015 g/ml) to ciprofloxacin and levofloxacin. Among the three fluoroquinolone-nonsusceptible meningococci, one isolate had ciprofloxacin and levofloxacin MIC values of 0.06 g/ml (intermediate) and two isolates had MIC values for both of these fluoroquinolones of 0.25 g/ml (resistant). These isolates (received from the CDC collection) were reported to have a mutation encoding the amino acid alteration T91I in the gyrA QRDR. These mutations were confirmed by JMI Laboratories. Furthermore, no additional mutations in the QRDR were observed in these strains and alterations in the regulator gene of efflux pump mtr were not present. CEM-101 had in vitro antimeningococcal activity that was comparable to those of ceftriaxone and the fluoroquinolones, all of which had MIC 50 and MIC 90 results of Յ0.015 g/ml (Table 1) . Rifampin (MIC 90 , 0.03 g/ml) was more active than either minocycline (MIC 90 , 0.25 g/ml) or TMP-SMX (MIC 90 , 2 g/ml). Among same-class comparator agents (MLS B ), CEM-101 was the most active compound, with an MIC 90 of Յ0.015 g/ml (telithromycin MIC 90 , 0.03 g/ml; azithromycin and clarithromycin MIC 90 s, 0.12 g/ml; erythromycin MIC 90 , 0.25 g/ml).
Current guidelines for control of community-acquired outbreaks of N. meningitidis via widespread vaccination programs have not been widely adopted in most countries and rely primarily on antimicrobial prophylaxis to reduce the risk to close a Criteria as published by the CLSI (7). The susceptible breakpoints were as follows: azithromycin, Յ2 g/ml; penicillin, Յ0.06 g/ml; ceftriaxone, Յ0.12 g/ml; ciprofloxacin, Յ0.03 g/ml; levofloxacin, Յ0.03 g/ml; minocycline, Յ2 g/ml; rifampin, Յ0.5 g/ml; and TMP-SMX, Յ0.12/2.4 g/ml. Ϫ, no interpretive criteria are available.
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contacts with the index patient (3, 21 (22) . The isolate from a patient in California may have been acquired by horizontal gene transfer from N. lactamica, a common commensal species (22) . The authors reporting these fluoroquinolone-resistant isolates also performed a carriage survey and documented a positivity rate of 7.5% for N. meningitidis carriers among close contacts and a convenience sample of the local population (22) . The emergence and potential spread of fluoroquinolone-resistant N. meningitidis are a serious public health problem, as this class of agents is currently recommended for contact prophylaxis. In contrast, all isolates were susceptible to azithromycin using the current CLSI breakpoint used for defining susceptibility (7) . These in vitro observations that CEM-101 had greater potency than other related MLS B class agents, including telithromycin (Ն2-fold), azithromycin and clarithromycin (Ն8-fold), and erythromycin (Ն16-fold), suggest that this new fluoroketolide could be an advantageous alternative for the prophylaxis of meningococcal case contacts, including fluoroquinolone-, TMP-SMX-, and penicillin-nonsusceptible clinical strains.
